A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective

Clinical Therapeutics

Volumn 32, Issue 4, 2010, Pages 717-728

  Nuijten, Mark ^a   Mittendorf, Thomas ^b,c  

^a Ars Accessus Medica   (Netherlands)

^b Health Economic Research and Consulting   (Germany)

^c LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

Cost effectiveness; Germany; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE COMPARISON; DRUG RESPONSE; ECONOMIC EVALUATION; FOLLOW UP; GERMANY; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; RELAPSE; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ADJUVANTS, IMMUNOLOGIC; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GERMANY; HUMANS; INTERFERON-BETA; MODELS, ECONOMIC; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 77952470429     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.03.019     Document Type: Article

References (47)

1. Hauser SL Multiple sclerosis and other demyelinating diseases. Harrison's Principles of Internal Medicine 1998, 2409-2412. McGraw-Hill, New York, NY. 14th ed. K.J. Isselbacher, E. Braunwald, J.D. Wilson (Eds.).
2. Harrison's Principles of Internal Medicine 1998, 2415-2419. McGraw-Hill, New York, NY. 14th ed. K.J. Isselbacher, E. Braunwald, J.D. Wilson (Eds.).
3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG Multiple sclerosis. N Engl J Med 2000, 343:938-952.
4. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: A geographically-based study. 2. Predictive value of the early clinical course. Brain 1989, 112:1419-1428.
5. Rieumont MJ, DeLuca SA Neuroimaging evaluation in multiple sclerosis. Am Fam Physician 1993, 48:273-276.
6. Hibberd PL The use and misuse of statistics for epidemiological studies of multiple sclerosis. Ann Neurol 1994, 36(Suppl 2):S218-S230.
7. Clark W Therapeutic advances: Beta-interferon for multiple sclerosis. J Clin Pharm Ther 1996, 21:195-199.
8. Goodkin DE, Hertsgaard D, Rudick RA Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 1989, 46:1107-1112.
9. Weatherall DJ, Ledingham JG, Warrell DA Oxford Textbook ofMedicine 1987, Oxford Medical Publications, Oxford, UK. 2nd ed.
10. Weinshenker BG The natural history of multiple sclerosis. Neurol Clin 1995, 13:119-146.
11. Rudick RA, Miller D, Clough JD, et al. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992, 49:1237-1242.
12. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis [published correction appears in Lancet. 1999;353:678]. Lancet 1998, 352:1498-1504. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
13. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661. The IFNB Multiple Sclerosis Group.
14. Placebo-controlled multicenter randomised trial of interferon beta-1b in treatment of sec ondary progressive multiple sclerosis. Lancet 1998, 352:1491-1497. European Study Group on Interferon Beta-1b in Secondary Progressive MS.
15. Catanzaro M, Weinert C Economic status of families living with multiple sclerosis. Int J Rehabil Res 1992, 15:209-218.
16. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ 2006, 7(Suppl 2):S34-S44.
17. Weinfeld FD, Baum HM The National Multiple Sclerosis Survey. Background and economic impact. Ann N Y Acad Sci 1984, 436:469-471.
18. Weinshenker BG, Issa M, Baskerville J Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology 1996, 46:1613-1619.
19. LaRocca N, Kalb R, Kendall P, Scheinberg L The role of disease and demographic factors in the employment of patients with multiple sclerosis. Arch Neurol 1982, 39:256.
20. Bauer HJ, Firnhaber W, Winkler W Prognostic criteria in multiple sclerosis. Ann N Y Acad Sci 1965, 122:542-551.
21. Grønning M, Hannisdal E, Mellgren SI Multivariate analyses of factors associated with unemployment in people with multiple sclerosis. J Neurol Neurosurg Psychiatry 1990, 53:388-390.
22. Murphy N, Confavreux C, Haas J, et al. Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 1998, 13:607-622. for the Cost of Multiple Sclerosis Study Group.
23. Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009, 15:543-555.
24. IQWiG (Institute for Quality and Efficiency in Health Care). Methods for assessment of the relation of benefit to costs in the German statutory health care system-version 2.0.
25. Accessed. http://www.igwig.de/index.805.html.
26. Koch M, Uyttenboogaart M, van Harten A, De Keyser J Factors associated with the risk of secondary progression in multiple sclerosis. Mult Scler 2008, 14:799-803.
27. Trojano M, Pellegrini F, Fuiani A, et al. New natural history ofinterferonbeta-treated relapsing multiple sclerosis. Ann Neurol 2007, 61:300-306.
28. Weinshenker BG, Issa M, Baskerville J Long-term and short-term outcome of multiple sclerosis: A 3-year follow-up study. Arch Neurol 1996, 53:353-358.
29. Grafvon der Schulenburg JM, Greiner W, Jost F, et al. German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus. Value Health 2008, 11:539-544. for the Hanover Consensus Group.
30. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS [published correction appears in Neurology. 2001; 57:1146]. Neurology 2001, 56:1628-1636. The PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group.
31. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon-beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002, 59:1496-1506. for the EVIDENCE (Evidence of Interferon Dose-Response: Euro pean North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group.
32. Evidence of interferon beta-1a dose response in relapsing remitting MS: The OWIMS Study. Neurology 1999, 53:679-686. The Once Weekly Interferon for MS Study Group.
33. Li DK, Paty DW Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-beta-1a in relapsing remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta-1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999, 46:197-206.
34. Jacobs LD, Cookfair DI, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis [published correction appears in Ann Neurol. 1996;40:480]. Ann Neurol 1996, 39:285-294. for the Multiple Sclerosis Collaborative Research Group (MSCRG).
35. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002, 59:1507-1517. for the European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators.
36. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995, 45:1277-1285. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
37. Paty DW, Li DK Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:662-667. for the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
38. Johnson KIP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results ofa phase III multicenter, double-blind placebo-controlled trial. Neurology 1995, 45:1268-1276. for the Copolymer 1 Multiple Sclerosis Study Group.
39. Comi G, Filippi M, Wolinsky JS European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001, 49:290-297. for the European/Canadian Glatiramer Acetate Study Group.
40. O'Brien JA, Ward AJ, Patrick AR, Caro J Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003, 3:17.
41. Germany annual inflation rates.
42. Accessed. http://www.worldwide-tax.com/germany/ger_inflation.asp.
43. Parkin D, McNamee P, Jacoby A, et al. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Asssess 1998, 2:iii-54.
44. Nuijten MJ, Hutton J Costeffectiveness analysis of interferon beta in multiple sclerosis: A Markov process analysis. Value Health 2002, 5:44-54.
45. Runmarker B, Andersson C, Odén A, Anderson O Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol 1994, 241:597-604.
46. Leitlinien der DGN 2008. Diagnostik and Therapie der Multiplen Sklerose.
47. Accessed. http://www.dmsg.de/dokumentearchiv/behandlungsleit_linien_der_dgn_stand_2008.pdf.